Dr Lina Eliasson
Dr Lina Eliasson PhD, CPsychol, is Advisory Board Member at CPASS, Founding Director at Sprout Behaviour Change and Breast Cancer Survivor
As a behavioural psychologist, Lina specialises in developing programmes to support those affected by chronic and terminal conditions, including patients, caregivers and healthcare providers. She gained her PhD in adherence to oral oncology drugs from UCL School of Pharmacy in 2011 and worked as a post-doc researcher at the Centre for Haematology at Hammersmith Hospital, Imperial College London, before swapping academia for a career in Industry. She has collaborated with numerous world-leading pharmaceutical and biotech companies in the UK, European and US markets across a wide range of disease categories, including immunology, oncology, haematology, gastroenterology, neurology, OBGYN and paediatric neurodegenerative disorders. She previously lead the European Clinical Outcomes Assessment team for ICON Plc, one of the world’s largest clinical research organisations.
On the 2nd January 2018, Lina was diagnosed with stage 2, grade 3, triple negative breast cancer and embarked on the most in-depth patient experience research of her career. Knowing the benefits that medical cannabis could potentially offer as an add-on therapy to conventional antiemetics to manage side effects of chemotherapy, she did her research and then announced to her healthcare team she wanted to combine their prescriptions with medical cannabis.